Dercum’s disease market research and analysis by treatment, by distribution channel, by end user - forecast till 2030. Dercum’s disease, also known as adiposis dolorosa, is a disease characterized by multiple growths called as lipomas. Lipomas are found under the epidermis and cause mild to severe discomfort when touched. It usually affects the trunk, upper arms, and upper legs. The Dercum’s disease market report by Market Research Future (MRFR) outlines drivers, opportunities, and challenges in a comprehensive manner.
Market Outlook
The global Dercum’s disease market is expected to touch a towering valuation by exhibiting 6.10 % CAGR from 2022 to 2030 (forecast period). Emergence of cases of rare diseases can drive the market demand. Ultrasound therapy and other methods of non-invasive diagnosis are bound to bolster the market growth. This is backed by the large healthcare expenditure accorded by governments for the welfare of citizens. Research studies linking the disease to obesity disorders as well as patient genetic history can bode well for the market.
Pharmaceutical corporations and government research institutions both perform clinical studies in an effort to stimulate the market for novel medications and chemicals. For instance, the new chemical RZL-012, which has neither a generic nor a brand name, has been observed to target and induce lipolysis in locations with lipomas. In a jointly performed clinical trial on women by Raziel Therapeutics and the University of Arizona, it demonstrated a fair amount of success.
Combination therapy may show to be a useful treatment option for diseased people. Drug companies may profit from stem cell therapies and payment plans for first prescription medications. Another business strategy that can benefit the worldwide Dercum's disease market is partnerships with hospital networks. But a rare disease's progress may be hampered by poor public awareness of it.
Competitive Outlook
- Hoffman-La Roche AG, St. Jude Medical Inc., Eli Lilly and Company, AstraZeneca PLC, Amgen, Johnson Johnson, Merck Co., Inc., Novartis, GlaxoSmithKline Plc, Valeant Pharmaceuticals, Syneron Medical, Abbvie, Inc., Alimed, Inc., and Pfizer, Inc. are some of the noteworthy players in the global Dercum’s disease market.
Segmentation Analysis
The global Dercum’s disease market report is segmented by treatment, distribution channel, and end-user.
By treatment, it is segmented into acupuncture, surgery, electrotherapy, medication, liposuction, and others. Electrotherapy can show the way for effective treatment for patients with the debilitating disease. Frequency rhythmic electrical modulation system (FREMS) and its subsequent success on administration to patients can drive the segment growth till 2023.
By distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and others.
By end-user, it is segmented into ambulatory surgical centers, hospitals, and others.
Regional Analysis
Europe, the Middle East Africa (MEA), Asia Pacific (APAC), and the Americas are regions covered in the Dercum’s disease market report.
The Americas are pegged to dominate the global market due to awareness of the disease by patients with the help of online forums. The large healthcare expenditure and an established healthcare sector with sufficient methods for treatment and diagnosis can propel the regional Dercum’s disease market growth. Large number of research and development activities dedicated for discerning the cause of the disease and development of reimbursement policies can work favorably for the market.
By providing patients with mesotherapy, a procedure that reduces aberrant forms beneath the skin, Europe can increase the value of the market as a whole. Injections of hormones, nonsteroidal anti-inflammatory medications, and other substances are used in the treatment. The market demand can be predicted by large public healthcare spending.
The APAC region can exhibit a commendable CAGR during the forecast period due to inflow of capital for research and development, economies with a well-developed healthcare framework, and high expendable income levels of citizens. Lastly, the MEA region possesses latent potential due to recent establishment of units dedicated for diagnosis and treatment of rare diseases.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]
Website: https://www.marketresearchfuture.com
